RGNX
REGENXBIO Inc.
Biotechnology
Market Cap$527M
5Y Perf.-72.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RGNX vs RCKT
Revenue, margins, valuation, and 5-year total return — side by side.
RCKT
Rocket Pharmaceuticals, Inc.
Biotechnology
Market Cap$398M
5Y Perf.-80.5%
RGNX vs RCKT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RGNX | RCKT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $527M | $398M |
| Revenue (TTM) | $161M | $0.00 |
| Net Income (TTM) | $-178M | $-223M |
| Gross Margin | 50.0% | — |
| Operating Margin | -96.0% | — |
| Total Debt | $82M | $25M |
| Cash & Equiv. | $58M | $78M |
RGNX vs RCKT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RGNX
RCKT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | 100 | 27.7 | -72.3% |
| Rocket Pharmaceutic… (RCKT) | 100 | 19.5 | -80.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RGNX vs RCKT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RGNX and RCKT are tied at the top with 2 categories each — the right choice depends on your priorities. Rocket Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
RGNX
REGENXBIO Inc.
The Long-Run Compounder
RGNX has the current edge in this matchup, primarily because of its strength in long-term compounding.
- 5.4% 10Y total return vs RCKT's -91.3%
- +43.9% vs RCKT's -45.2%
- -33.9% ROA vs RCKT's -67.5%, ROIC -53.8% vs -63.2%
Best for: long-term compounding
RCKT
Rocket Pharmaceuticals, Inc.
The Income Pick
RCKT is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.31
- EPS growth 26.4%
- Lower volatility, beta 1.31, Low D/E 9.0%, current ratio 6.38x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RCKT | 10.5% revenue growth vs RGNX's -7.7% |
| Stability / Safety | RCKT | Beta 1.31 vs RGNX's 2.59, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RGNX | +43.9% vs RCKT's -45.2% |
| Efficiency (ROA) | RGNX | -33.9% ROA vs RCKT's -67.5%, ROIC -53.8% vs -63.2% |
RGNX vs RCKT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
RGNX vs RCKT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRGNXLAGGINGRCKT
RCKTRocket Pharmaceutical…
1leads
RGNXREGENXBIO Inc.
1leads
6 Total Categories
CATEGORYLEADERvs RCKTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RCKT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
RGNX5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RCKT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RGNX and RCKT operate at a comparable scale, with $161M and $0 in trailing revenue.
| Metric | RGNXREGENXBIO Inc. | RCKTRocket Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $161M | $0 |
| EBITDAEarnings before interest/tax | -$139M | -$232M |
| Net IncomeAfter-tax profit | -$178M | -$223M |
| Free Cash FlowCash after capex | -$106M | -$190M |
| Gross MarginGross profit ÷ Revenue | +50.0% | — |
| Operating MarginEBIT ÷ Revenue | -96.0% | — |
| Net MarginNet income ÷ Revenue | -110.3% | — |
| FCF MarginFCF ÷ Revenue | -65.9% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.9% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -2.6% | +38.7% |
RCKT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — RGNX and RCKT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | RGNXREGENXBIO Inc. | RCKTRocket Pharmaceut… |
|---|---|---|
| Market CapShares × price | $527M | $398M |
| Enterprise ValueMkt cap + debt − cash | $552M | $345M |
| Trailing P/EPrice ÷ TTM EPS | -2.27x | -1.83x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 6.33x | — |
| Price / BookPrice ÷ Book value/share | 1.99x | 1.47x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — RGNX and RCKT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — RGNX and RCKT each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
RCKT delivers a -80.5% return on equity — every $100 of shareholder capital generates $-80 in annual profit, vs $-110 for RGNX. RCKT carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to RGNX's 0.32x. On the Piotroski fundamental quality scale (0–9), RGNX scores 4/9 vs RCKT's 1/9, reflecting mixed financial health.
| Metric | RGNXREGENXBIO Inc. | RCKTRocket Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -110.2% | -80.5% |
| ROA (TTM)Return on assets | -33.9% | -67.5% |
| ROICReturn on invested capital | -53.8% | -63.2% |
| ROCEReturn on capital employed | -57.9% | -58.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.32x | 0.09x |
| Net DebtTotal debt minus cash | $25M | -$53M |
| Cash & Equiv.Liquid assets | $58M | $78M |
| Total DebtShort + long-term debt | $82M | $25M |
| Interest CoverageEBIT ÷ Interest expense | -3.22x | — |
Evenly matched — RGNX and RCKT each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RGNX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RGNX five years ago would be worth $2,873 today (with dividends reinvested), compared to $838 for RCKT. Over the past 12 months, RGNX leads with a +43.9% total return vs RCKT's -45.2%. The 3-year compound annual growth rate (CAGR) favors RGNX at -17.3% vs RCKT's -44.4% — a key indicator of consistent wealth creation.
| Metric | RGNXREGENXBIO Inc. | RCKTRocket Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -23.2% | +6.1% |
| 1-Year ReturnPast 12 months | +43.9% | -45.2% |
| 3-Year ReturnCumulative with dividends | -43.5% | -82.8% |
| 5-Year ReturnCumulative with dividends | -71.3% | -91.6% |
| 10-Year ReturnCumulative with dividends | +5.4% | -91.3% |
| CAGR (3Y)Annualised 3-year return | -17.3% | -44.4% |
RGNX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — RGNX and RCKT each lead in 1 of 2 comparable metrics.
Risk & Volatility
RCKT is the less volatile stock with a 1.31 beta — it tends to amplify market swings less than RGNX's 2.59 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RGNX currently trades 64.4% from its 52-week high vs RCKT's 49.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RGNXREGENXBIO Inc. | RCKTRocket Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.59x | 1.31x |
| 52-Week HighHighest price in past year | $16.19 | $7.39 |
| 52-Week LowLowest price in past year | $6.89 | $2.19 |
| % of 52W HighCurrent price vs 52-week peak | +64.4% | +49.7% |
| RSI (14)Momentum oscillator 0–100 | 64.5 | 54.4 |
| Avg Volume (50D)Average daily shares traded | 741K | 3.5M |
Evenly matched — RGNX and RCKT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates RGNX as "Buy" and RCKT as "Buy". Consensus price targets imply 147.1% upside for RGNX (target: $26) vs 36.2% for RCKT (target: $5).
| Metric | RGNXREGENXBIO Inc. | RCKTRocket Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $25.75 | $5.00 |
| # AnalystsCovering analysts | 20 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RCKT leads in 1 of 6 categories (Income & Cash Flow). RGNX leads in 1 (Total Returns). 3 tied.
Best OverallREGENXBIO Inc. (RGNX)Leads 1 of 6 categories
Loading custom metrics...
RGNX vs RCKT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RGNX or RCKT a better buy right now?
Analysts rate REGENXBIO Inc.
(RGNX) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RGNX or RCKT?
Over the past 5 years, REGENXBIO Inc.
(RGNX) delivered a total return of -71. 3%, compared to -91. 6% for Rocket Pharmaceuticals, Inc. (RCKT). Over 10 years, the gap is even starker: RGNX returned +5. 4% versus RCKT's -91. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RGNX or RCKT?
By beta (market sensitivity over 5 years), Rocket Pharmaceuticals, Inc.
(RCKT) is the lower-risk stock at 1. 31β versus REGENXBIO Inc. 's 2. 59β — meaning RGNX is approximately 97% more volatile than RCKT relative to the S&P 500. On balance sheet safety, Rocket Pharmaceuticals, Inc. (RCKT) carries a lower debt/equity ratio of 9% versus 32% for REGENXBIO Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — RGNX or RCKT?
On earnings-per-share growth, the picture is similar: Rocket Pharmaceuticals, Inc.
grew EPS 26. 4% year-over-year, compared to 23. 8% for REGENXBIO Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RGNX or RCKT?
Rocket Pharmaceuticals, Inc.
(RCKT) is the more profitable company, earning 0. 0% net margin versus -272. 5% for REGENXBIO Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCKT leads at 0. 0% versus -280. 0% for RGNX. At the gross margin level — before operating expenses — RGNX leads at 59. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — RGNX or RCKT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RGNX or RCKT better for a retirement portfolio?
For long-horizon retirement investors, Rocket Pharmaceuticals, Inc.
(RCKT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. REGENXBIO Inc. (RGNX) carries a higher beta of 2. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RCKT: -91. 3%, RGNX: +5. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RGNX and RCKT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.